


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
HSMN NewsFeed - 21 May 2009
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
HSMN NewsFeed - 21 May 2009
Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD
Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD
HSMN NewsFeed - 20 May 2009
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
HSMN NewsFeed - 19 May 2009
Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg
Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg
HSMN NewsFeed - 19 May 2009
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
HSMN NewsFeed - 19 May 2009
Emisphere Technologies Appoints Franklin M. Berger to Its Board of Directors
Emisphere Technologies Appoints Franklin M. Berger to Its Board of Directors
HSMN NewsFeed - 19 May 2009
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
HSMN NewsFeed - 18 May 2009
U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold
U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold
HSMN NewsFeed - 14 May 2009
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
HSMN NewsFeed - 13 May 2009
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
HSMN NewsFeed - 13 May 2009
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
HSMN NewsFeed - 12 May 2009
Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
HSMN NewsFeed - 12 May 2009
AstraZeneca Secures Approval for Nexium (esomeprazole) In Peptic Ulcer Bleeding
AstraZeneca Secures Approval for Nexium (esomeprazole) In Peptic Ulcer Bleeding
HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
HSMN NewsFeed - 11 May 2009
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
HSMN NewsFeed - 11 May 2009
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
DUSA Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
HSMN NewsFeed - 8 May 2009
Lannett Company Receives FDA Approval for Pilocarpine HCI Tablets 7.5 mg Strength
Lannett Company Receives FDA Approval for Pilocarpine HCI Tablets 7.5 mg Strength
HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
HSMN NewsFeed - 7 May 2009
Paladin Labs and Isotechnika Inc. Form Partnership for Commercialization of Voclosporin
Paladin Labs and Isotechnika Inc. Form Partnership for Commercialization of Voclosporin
HSMN NewsFeed - 7 May 2009
Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
HSMN NewsFeed - 6 May 2009
VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round
VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round
HSMN NewsFeed - 6 May 2009
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
HSMN NewsFeed - 5 May 2009
Takeda Global Research & Development Center, Inc., U.S. Names Dr. Azmi Nabulsi President
Takeda Global Research & Development Center, Inc., U.S. Names Dr. Azmi Nabulsi President
HSMN NewsFeed - 5 May 2009
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
HSMN NewsFeed - 5 May 2009
ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
HSMN NewsFeed - 5 May 2009
Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Italy
Stellar Pharmaceuticals Inc. Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Italy
HSMN NewsFeed - 4 May 2009
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
HSMN NewsFeed - 4 May 2009
Biovail Enters into Collaboration and License Agreement with Acadia for Pimavanserin
Biovail Enters into Collaboration and License Agreement with Acadia for Pimavanserin
HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
HSMN NewsFeed - 29 Apr 2009
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
HSMN NewsFeed - 29 Apr 2009
Aquilion ONE CT System Enables St. Vincent Healthcare to Expand Service Lines and Improve Patient Care
Aquilion ONE CT System Enables St. Vincent Healthcare to Expand Service Lines and Improve Patient Care
HSMN NewsFeed - 28 Apr 2009
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
HSMN NewsFeed - 24 Apr 2009
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
HSMN NewsFeed - 23 Apr 2009
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
HSMN NewsFeed - 23 Apr 2009
DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
HSMN NewsFeed - 23 Apr 2009
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
HSMN NewsFeed - 22 Apr 2009
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
HSMN NewsFeed - 20 Apr 2009
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
HSMN NewsFeed - 20 Apr 2009
GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
HSMN NewsFeed - 20 Apr 2009
SpePharm Announces the European Launches of Two New Products: MuGard and Xerotin
SpePharm Announces the European Launches of Two New Products: MuGard and Xerotin
HSMN NewsFeed - 15 Apr 2009
TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
HSMN NewsFeed - 15 Apr 2009
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer
HSMN NewsFeed - 14 Apr 2009
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
HSMN NewsFeed - 13 Apr 2009
Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
HSMN NewsFeed - 13 Apr 2009
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
HSMN NewsFeed - 10 Apr 2009
Pfizer's Oncology Business Unit Appoints Vice President of Medical Affairs
Pfizer's Oncology Business Unit Appoints Vice President of Medical Affairs
HSMN NewsFeed - 10 Apr 2009
Molecular Templates Inc. Secures $2.5 Million in Series A Financing from Sant Ventures
Molecular Templates Inc. Secures $2.5 Million in Series A Financing from Sant Ventures
HSMN NewsFeed - 8 Apr 2009
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer
HSMN NewsFeed - 7 Apr 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer
TransMolecular Appoints Robert Radie President and Chief Executive Officer
HSMN NewsFeed - 7 Apr 2009
IntelGenx Corp. and Cary Pharmaceuticals File NDA for CPI-300 Antidepressant
IntelGenx Corp. and Cary Pharmaceuticals File NDA for CPI-300 Antidepressant
HSMN NewsFeed - 2 Apr 2009
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
HSMN NewsFeed - 2 Apr 2009
Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
HSMN NewsFeed - 2 Apr 2009
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
HSMN NewsFeed - 2 Apr 2009
RXi Pharmaceuticals Announces an Addition, Promotions Among Senior Management Team
RXi Pharmaceuticals Announces an Addition, Promotions Among Senior Management Team
HSMN NewsFeed - 2 Apr 2009
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
HSMN NewsFeed - 1 Apr 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
HSMN NewsFeed - 31 Mar 2009
GE Healthcare Announces Data from Phase III Study of AdreView in Heart Failure Patients
GE Healthcare Announces Data from Phase III Study of AdreView in Heart Failure Patients
HSMN NewsFeed - 31 Mar 2009
TYRX Announces the Appointment of George D. Landau as Vice President, Business Development
TYRX Announces the Appointment of George D. Landau as Vice President, Business Development
HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
HSMN NewsFeed - 30 Mar 2009
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
HSMN NewsFeed - 30 Mar 2009
BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
